Noteworthy

Mar 01, 2011
Pharmaceutical Executive
Can PhRMA's own business model synch with industry's Pharm Exec takes a closer look at PhRMA's new leadership.
Mar 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
A sneak preview of The Avoca Group's 2011 Annual Survey on CRO and Industry Relationships
Mar 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The Federal Circuit court continues its trend in tightening the standards for establishing patent damages by leapfrogging a stalled legislative process
Mar 01, 2011
Pharmaceutical Executive
FDA's Sentinel Initiative raises broader questions about tapping patient information and health IT for comparative studies in drug development
Mar 01, 2011
Pharmaceutical Executive
Negative views regarding pharma are on the rise, but vaccines help keep the focus on the positives of innovation
Mar 01, 2011
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Pharm Exec's annual feature applauding the people behind the best of pharma advertising over the past year
Mar 01, 2011
Pharmaceutical Executive
Pharma can be an insular industry, with limited capacity to gaze beyond its own narrow frame of vision
Mar 01, 2011
Pharmaceutical Executive
When dealing with the pharmaceutical marketplace, why is keeping things simple so complex?
Mar 01, 2011
Pharmaceutical Executive
A highlight of the Hay Group's annual study of Sales Force Effectiveness, focusing on managed care markets
Mar 01, 2011
Pharmaceutical Executive
With an emphasis on short-term objectives rather than long-term goals, pharma is missing a huge opportunity in applying market science to drive adherence
native1_300x100
lorem ipsum